Navigation Links
BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer
Date:5/28/2008

n. "The combination of a PARP inhibitor such as BSI-201 which specifically targets uterine tumors in a unique way may boost the effects of common chemotherapy regimen. We hope this drug will play a transformative role in the way we approach treatment."

Uterine cancer is the most common gynecological tumor, and the fourth most-common type of tumor in women. Forty thousand new diagnoses are made each year in the United States.

"Because PARP is expressed at high levels in uterine cancer and particularly MMT, we believe that BSI-201 has the potential to selectively target these highly aggressive and poorly treated tumors," said BiPar Executive Vice President Barry Sherman, M.D. "This will be our third study designed around our gene expression data, which has been invaluable in selecting types of cancer that will most likely respond to PARP inhibition."

About BiPar Sciences

BiPar Sciences is a drug development company with a therapeutic focus on exploring novel mechanisms of action in oncology. The lead development program is based on DNA repair, specifically with poly ADP-ribose polymerase (PARP) inhibitors. The lead product within that program is BSI-201, a platform drug with the potential to be a superior new treatment across a range of tumor types, both as monotherapy and in combination with chemotherapy. The company is currently testing BSI-201 in a range of Phase 2 trials in breast, brain, uterine and ovarian cancer.


'/>"/>
SOURCE BiPar Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
2. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
3. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
4. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
5. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
6. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
7. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
8. Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives
9. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
10. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
11. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014  Australian drug delivery company, Phosphagenics Limited (ASX: ... A$19.3 million via a placement of A$16.3 million to ... U.S., Asia and ... purchase plan (SPP) to be offered to existing shareholders. ... two tranches. "This capital raising positions us ...
(Date:7/11/2014)... 11, 2014 Research and Markets ( ... "Immunoprotein Diagnostic Testing Market - Forecasts to ... of 6% and is expected to be valued ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... has been segmented according to immunoprotein types which ...
(Date:7/11/2014)... 2014 Neurelis, Inc. ("Neurelis") today announced an ... option held by Biotie to purchase Neurelis, clearing the ... (intranasal diazepam) for pediatric and adult epilepsy patients who ... year, Biotie has advanced the development program for NRL-1 ... clinical work required for NDA submission to the FDA.  ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... Aethlon Medical, Inc. (OTC Bulletin Board: ... to address infectious disease and cancer, announced today that ... Medicity Institute (Medicity) has approved a treatment program entitled: ... Infection in Combination with Standard of Care (SOC) Drug ...
... will help its guests reach their well-being goals by ... cold and flu season. Beginning Sept. 1, 2010, the ... Target Pharmacy and Target Clinic locations nationwide. Continuing its ... again offering the seasonal flu vaccine at the low ...
Cached Medicine Technology:Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program 2Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program 3Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program 4Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program 5Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program 6Target to Serve as Prevention HQ this Flu Season 2
(Date:7/12/2014)... (PRWEB) July 12, 2014 The report, ... Alkyd Resins) Market by Application & Geography – Trends ... market with analysis and forecasting of market volume and ... of the derivatives separately. The market of phthalic anhydride ... in 2013 to $8,415.89 million by 2018, with a ...
(Date:7/12/2014)... The Security Analytics market is estimated to grow from ... at an expected CAGR of 9.7% for the period ... increasing number of security breaches, continued line of sophisticated ... organizations are enormous. Vendors in the security analytics market ... develop better and more secure systems. , There has ...
(Date:7/12/2014)... 2014 (HealthDay News) -- Burn injuries increase in the summer ... say burn experts. Among those most vulnerable to these seasonal ... vulnerable and often get burned by putting their hands on ... of the burn unit at Loyola University Medical Center in ... old adage of ,When you play with fire, you get ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 As DePuy ... forward in U.S. courts, Bernstein Liebhard LLP notes the ... ion levels to the failure of metal-on-metal hip replacements. ... of The Journal of Bone & Joint Surgery, looked ... Articular Surface Replacement prostheses at least twelve months earlier. ...
(Date:7/12/2014)... 12, 2014 Doylestown Hospital recently conducted ... of men’s health questions. Paddock tackles topics including ... why women live longer than men, and testosterone replacement ... Made Simple featured on Doylestown Hospital’s website, Dr. ... at any age. If you notice pain, bulging, or ...
Breaking Medicine News(10 mins):Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Burn Injuries More Common in Summer 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2
... because it comes with a computer's worst enemy: heat . ... and entire systems to become slower and less stable. A hot ... in fact, spell the end of a computer altogether. ... cool enough in the summertime. By paying attention to how much ...
... suggests why the commonly prescribed cholesterol-lowering drug ezetimibe (Zetia) ... at Wake Forest University School of Medicine, is reported ... will appear in the July 2 print issue. ... works by preventing cells in the intestine from absorbing ...
... scientist at annual conference of the European Society of ... can undergo chromosomal modifications. , Ms ... Hospital, Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel, ... that the results of preimplantation genetic screening (PGS) for ...
... filled the area in and around the football stadium in ... Puget Sound Race for the Cure . About 1,200 of ... others were running to honor family members who had died ... T-shirts and sporting the medallions awarded by the event organizers. ...
... Smile does seem to be working wonders for victims of ... of Cosmetic Dentistry, the nonprofit group is putting domestic violence ... ,To date, 500 applicants have been treated in ... or social worker must confirm that the injuries were caused ...
... the Toronto police busted a global Internet pedophile ring ... rescued more than 31 kids.700 suspects were rounded ... pornography network from a British-based website. The ring ... the Light of Our Lives" that featured images of ...
Cached Medicine News:Health News:Hot Tips for Keeping Your PC Cool in Summer 2Health News:Hot Tips for Keeping Your PC Cool in Summer 3Health News:Animal Research Uncovers Another Mechanism of Cholesterol Lowering Drug 2Health News:Preimplanted Genetic Screening Should Be Interpreted With Caution 2Health News:Annual Cancer Run Draws Huge Response in US 2Health News:US Dentists Help Victims of Domestic Violence Smile Again 2Health News:Thirty One Kids Rescued from a Pedophile Ring 2
Blunt tipped forceps wlth a small grasping platform on each tip. For grasping fine membranes or grasping membranes adherent to the retinal surface....
Blunt tipped forceps with a smooth, pliable silicone coating on the entire interior surface of the tip. For removal of foreign bodies or atraumatic tissue grasping....
Blunt tipped forceps with small, slightly rounded tips angled perpendicular to the shaft. For grasping peripheral membranes....
Blunt tipped forceps with small, slightly pointed grasping platforms on each tip. For general purpose (fine) membrane grasping and grasping membranes adherent to the retlnal surface....
Medicine Products: